Table 1.

Baseline Characteristics of the 396 HIV-Infected Subjects in the Study Cohort, Overall and by HCV RNA Status

	Total sample (N = 396)	HCV RNA+ (N = 199)	HCV RNA- (N = 197)	p-Value
Age (y), mean (SD)	42.5 (7.4)	43.9 (7.0)	40.9 (7.5)	<0.0001
Gender
Female	25%	27%	23%	0.42
Male	75%	73%	77%
Race
Black	41%	38%	44%	0.46
White	33%	34%	32%
Other	26%	28%	24%
Median CD4 count^a (IQR)	403 (238, 624)	356 (231, 542)	424 (257, 655)	0.02
Median log₁₀ HIV RNA^b (IQR)	2.95 (1.57, 4.14)	2.92 (1.57, 4.14)	3.03 (1.40, 4.18)	0.94
Undetectable HIV RNA
Yes	31%	29%	33%	0.49
No	69%	71%	67%
HIV ART status^c
Adherent	47%	50%	44%	0.48
Not adherent	15%	15%	16%
Not on meds	38%	36%	40%
Injection drug use ever^d
Yes	55%	89%	20%	<.0001
No	45%	11%	80%
Injection drug use, past 6 mo^d
Yes	14%	23%	5%	<.0001
No	86%	77%	95%
Drug dependence, past 12 mo
Yes	43%	44%	40%	0.42
No	57%	56%	60%
Homeless
Yes	25%	29%	20%	0.06
No	75%	71%	80%
Lifetime alcohol dependence
Dependence	70%	74%	66%	0.14
Abuse	18%	17%	19%
No diagnosis	12%	9%	15%
Alcohol dependence, past 6 mo
Dependence	10%	11%	9%	0.70
Abuse	2%	2%	2%
No diagnosis	88%	87%	89%
Alcohol consumption, past mo^d
None	58%	63%	53%	0.09
Moderate	11%	8%	13%
Heavy	31%	29%	34%
Participated in previous HIV study^e
Yes	38%	43%	33%	0.04
No	62%	57%	67%
Time since diagnosis of HIV (y), mean (SD)	9.2 (4.9)	9.8 (4.9)	8.6 (4.8)	0.02
Time since starting HIV ART (y), mean (SD)	6.9 (4.1)	7.1 (4.2)	6.7 (4.0)	0.30

N = 375, 187, and 188, respectively.

N = 361, 180, and 181, respectively.

Adherent: N = 185, 99, and 86, respectively; Not adherent: N = 61, 29, and 32, respectively; Not on meds: N = 150, 71, and 79, respectively.

N = 396, 200, and 196, respectively.

“Yes” indicates subjects were previously enrolled in an observational cohort study conducted by the study investigators.

HIV, human immunodeficiency virus; ART, antiretroviral therapy.